Non-Confidential
Technology Disclosure

Title: Methods and compositions for controlling efficacy and specificity of RNA silencing

Investigators: Phillip D. Zamore, Ph.D., Guiliang Tang, Gyorgy Hutvagner, Martin Simard, and Dianne Schwarz, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School

Description: This invention describes siRNA strand design rules and compositions to enhance the efficiency and specificity of RNAi. Dr. Zamore et al. have found that small variations in siRNA sequences have profound and predictable effects on strand entry into the RNA-induced silencing complex (RISC), thereby enabling the design of specific imperfections in silencing RNAs that enhance targeting and cleavage. RNAi agents designed with these rules also reduces or eliminates undesired silencing of non-target genes.

Application: Methodologies and reagents included within this invention may be used for:
• Enhancing the efficacy and specificity of RNAi
• Decreasing silencing of inadvertent target genes
• Novel therapeutics and gene therapy
• Improving upon basic research applications of RNAi
• Research reagents such as siRNAs, shRNAs, vectors and transgenes.

Advantage: This invention provides the specific design of RNAi agents which provide better targeting and cleavage of target genes to allow for more control in mediating gene silencing.

Publication: Cell 2003.115: 199-208
Genes and Development 2003.17: 49-63

Patent Status: Patent pending, #20050186586 and #20060009402

Licensing Status: Research Reagent Field Available to License

Docket: UMMC 03-103, 03-123

Contact: Lisa L. Decker, Ph.D.
Associate Director
Phone: (508) 856-5055, Fax: (508)856-1482
Lisa.Decker@umassmed.edu